Corona Remedies: FY26 Revenue up 17.3% to ₹1,403.2 Cr, PAT up 33.4%
RESULTS
▲ Positive Development
LOW RISK
📅 Filed on BSE: 11 May 2026, 05:42 PM IST · BSE ID: 75a44f02-10fd-4687-825c-dc0c6f3a092b
View Original BSE Filing (PDF)
💡
In Simple Terms
The company’s annual sales increased by 17.3% and its profits grew by 33.4% compared to last year.
🤖 AI Summary
- Corona Remedies reported 17.3% YoY revenue growth in FY26 to ₹1,403.2 Cr
- Profit After Tax (PAT1) increased 33.4% in FY26, reaching ₹199.4 Cr
- Q4FY26 revenue grew 20.2% YoY to ₹353.1 Cr, PAT1 up 43.7% to ₹45.3 Cr
- Acquired WOKADINE, marking entry into the ₹648 Cr Povidone Iodine market
- Board recommended a final dividend of ₹10 per equity share for FY26
🔢 Key Numbers — exact figures from BSE filing, not rounded
Revenue from Operations (FY26)
₹1,403.2 Cr
17.3%
Profit After Tax1 (FY26)
₹199.4 Cr
33.4%
Revenue from Operations (Q4FY26)
₹353.1 Cr
20.2%
Profit After Tax1 (Q4FY26)
₹45.3 Cr
43.7%
EBITDA Margin (FY26)
20.9%
85 bps
PAT Margin1 (FY26)
14.2%
172 bps
🏢 How This Affects the Company
Revenue growth of 17.3% in FY26 and 20.2% in Q4FY26 indicates expansion in sales. The acquisition of WOKADINE facilitates entry into the Povidone Iodine market, expanding the company's product portfolio and addressable market.
Profit After Tax (PAT1) increased by 33.4% in FY26 and 43.7% in Q4FY26, supported by operating leverage and cost optimization, leading to improved PAT margins. The acquisition was funded through internal accruals, indicating efficient capital deployment.
Relaunching key brands and establishing a dedicated team for the infertility segment reflects strategic focus on portfolio expansion and high-growth specialty areas. EAEU-GMP certification enables market entry into Russia, Belarus, Kazakhstan, Armenia, and Kyrgyzstan.
👥 What This Means For Shareholders
✅
Action Required
Shareholders are not required to take any immediate action based on this press release.
👤
Who Is Affected
All shareholders will be affected by the company's financial performance. Shareholders as of the record date (June 19, 2026) will be eligible for the ₹10 per equity share final dividend.
🔍
Management Signal
The Board's recommendation of a ₹10 final dividend and focus on strategic acquisitions and portfolio expansion signals management's confidence in financial health and growth trajectory.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
AGM date — confirm final dividend approval and payment timeline
Next quarterly results — observe sustainability of revenue and PAT growth
Updates on WOKADINE integration — assess market share in Povidone Iodine
LOW RISK
The filing indicates strong financial performance and strategic initiatives with no immediate risks flagged.
💡 Investor Takeaway
Corona Remedies reported FY26 Revenue from Operations of ₹1,403.2 Cr, up 17.3% YoY, and Profit After Tax1 of ₹199.4 Cr, a 33.4% YoY increase. The company acquired WOKADINE, marking entry into the ₹648 Cr Povidone Iodine market, funded via internal accruals.
⚖️ Strengths & Concerns
✅ Positives
- FY26 Revenue from Operations grew 17.3% to ₹1,403.2 Cr, indicating sustained business expansion.
- Profit After Tax1 for FY26 increased 33.4% to ₹199.4 Cr, demonstrating enhanced profitability.
- Strategic acquisition of WOKADINE facilitates entry into the ₹648 Cr Povidone Iodine market.
- PAT Margin1 for FY26 improved by 172 bps to 14.2%, reflecting cost optimization and operating leverage.
⚠️ Concerns
- Q4FY26 EBITDA Margin decreased by 89 bps to 17.6% compared to 18.5% in Q4FY25.
- FY26 Profit After Tax1 includes a one-time statutory impact of ₹14.3 Crores (Post Tax) from the New Labor Code.
📅 Company Track Record
Corona Remedies Limited, founded in 2004, has consistently improved its market position, rising to 27th rank in India from 32nd three years ago. The Board previously approved FY26 results and recommended a ₹10 final dividend per equity share for a record date of June 19, 2026.
Based on publicly available historical data. For context only.